SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Drug DiscoveryArtificial IntelligenceAI Drug Discovery

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 2171593

Cover Image

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 2171593

AI in Protein Engineering Market, AI Tools, Application, Protein Type, Process, End User - Global Forecast to 2031

PUBLISHED:
PAGES: 436 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 4950
PDF (5-user License)
USD 6650
PDF (Corporate License)
USD 8150
PDF (Global License)
USD 10000

Add to Cart

Description

Table of Contents

List of Tables

The global AI in protein engineering market is projected to reach USD 3.82 billion by 2031 from USD 1.44 billion in 2026, at a CAGR of 21.6% from 2026 to 2031. Growth in the AI in protein engineering market is driven by rising pharmaceutical R&D expenditure, increasing drug development costs, and the need to improve the productivity of protein discovery and design.

Scope of the Report
Years Considered for the Study2026-2031
Base Year2025
Forecast Period2026-2031
Units ConsideredValue (USD billion)
SegmentsOffering, AI Tool, Application, Protein Type, Protein Engineering Process, End User
Regions coveredNorth America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

The 25 selected drugmakers analyzed by IntuitionLabs reported approximately USD 185 billion in combined R&D spending in 2025, with Merck & Co. spending USD 15.8 billion, Johnson & Johnson USD 14.7 billion, and Eli Lilly USD 13.3 billion. Improving returns from these investments is especially important, as the average R&D cost per approved drug asset rose from USD 2.23 billion in 2024 to USD 2.67 billion in 2025. AI is increasingly viewed as a lever to address these costs and improve the efficiency of drug discovery and development. However, adoption remains constrained by implementation complexity and uncertain ROI; 71% of life sciences executives reported AI deployment progress, but only 45% reported measurable performance gains, while 61% identified external partnerships as important for accessing AI capabilities.

AI in Protein Engineering Market - IMG1

"In 2025, antibodies held the largest share of the market, by protein type"

By protein type, antibodies represented the largest share of the AI in protein engineering market in 2025. This leadership stems from the growing development of antibody-based therapeutics and the increasing need to improve the efficiency of antibody discovery and optimization. Pharmaceutical and biotechnology companies extensively utilize AI-powered protein engineering tools for antibody sequence generation, affinity optimization, specificity prediction, developability assessment, and stability optimization. The rising focus on innovative antibody modalities, including bispecific antibodies, antibody-drug conjugates, and other next-generation biologics, has further increased demand for AI-enabled antibody engineering. Moreover, generative AI and protein language models can explore large sequence spaces, prioritize promising candidates, and reduce experimental iterations, encouraging greater adoption of AI-based antibody engineering platforms.

"Protein optimization to register highest CAGR in the market, by process"

By process, protein optimization is expected to be the fastest-growing segment in the AI in protein engineering market, driven by the need to improve protein activity, stability, specificity, affinity, and developability while reducing experimental iterations. AI-enabled optimization is demonstrating measurable improvements; an AI-guided closed-loop platform achieved a 57-fold increase in enzyme activity within five engineering cycles and up to 104-fold improvement for another enzyme. AI-based computational filtering has also improved experimental success rates by 50-150%, enabling faster prioritization of high-performing protein variants. These advances are expected to accelerate adoption of protein language models, generative AI, and machine-learning-based optimization across pharmaceutical, biotechnology, and industrial protein-engineering workflows.

"Asia Pacific to witness the highest growth rate during the forecast period"

The Asia Pacific region is projected to register the highest growth rate in the AI in protein engineering market during the forecast period, supported by the rapid development of AI-enabled protein design capabilities, expanding computational biology infrastructure, and increasing integration of AI with high-throughput experimentation. In China, researchers at Shanghai Jiao Tong University developed the Venus-Pod protein dataset, which contains more than 9 billion protein sequences, including 2.43 billion antibody sequences and 500 million functionally annotated sequences, providing a strong foundation for AI-driven protein design and optimization. The region is also advancing AI-enabled experimental workflows; an automated platform developed in China can perform more than 100 protein expression, purification, and testing tasks within 24 hours, nearly 10 times as efficiently as manual workflows. In Japan, RevolKa raised JPY 210 million (approximately USD 1.4 million) in May 2025 to advance its AI-powered aiProtein technology and therapeutic programs. Furthermore, Singapore-based research at the National University of Singapore is integrating machine learning with ultra-high-throughput sorting and next-generation sequencing to generate large-scale sequence-function datasets for AI-driven protein engineering. These developments, alongside the growing ecosystem of AI-protein engineering startups, research institutes, and automated biofoundries, are expected to accelerate adoption of generative AI, protein language models, and machine learning across protein discovery, optimization, antibody engineering, and de novo protein design in APAC.

The breakdown of primary participants is as mentioned below:

  • By Company Type - Tier 1: 34%, Tier 2: 46%, and Tier 3: 20%
  • By Designation - C-level: 35%, Director-level: 25%, and Others: 40%
  • By Region - North America: 30%, Europe: 45%, Asia Pacific: 20%, Middle East & Africa: 3%, Latin America: 2%

Key Players in the AI in Protein Engineering Market

The key players functioning in the AI in protein engineering market include Schrodinger, Inc. (US), XtalPi (China), Dassault Systemes (France), NVIDIA Corporation (US), Generate:Biomedicines (US), Absci Corp. (US), Insilico Medicine (US), Isomorphic Labs (UK), among others.

Research Coverage:

This research report categorizes the AI in protein engineering market by offering (software/platforms, services), by AI tool (machine learning & deep learning, protein language models, generative AI, structure-based AI, other tools), by application (next-generation biologics, molecular glues, data generation, antibody discovery and optimization, enzyme engineering, de novo protein design, protein stability and developability optimization, other applications), by protein type (antibodies, enzymes, cytokines & growth factors, peptides, fusion proteins, miniproteins, other proteins), by protein engineering process (protein discovery, protein design, protein optimization, protein characterization, experimental validation), by end user (pharmaceutical & biotechnology companies, academic & research institutes, contract research organizations, industrial biotechnology companies, other end users), and by region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa). The report covers detailed information on major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the AI in protein engineering market. A detailed analysis of key industry players provides insights into their business overview, solutions, and services; key strategies; and recent developments associated with the AI in protein engineering market. This report covers the competitive analysis of startups in the AI in protein engineering market ecosystem.

Reasons to Buy the Report

This report will help established firms and new entrants/smaller firms gauge the market's pulse, which, in turn, can help them gain a greater share of the market. Firms purchasing the report can use one or more of the strategies below to strengthen their market position.

This report provides insights on:

  • Analysis of key drivers (increasing adoption of generative ai and protein foundation models, rising demand for next-generation biologics and engineered proteins, increasing availability of protein sequence, structure, and experimental datasets), restraints (limited availability of high-quality experimentally validated protein data, high cost and complexity of experimental validation), opportunities (expansion of AI-designed de novo proteins, growth of AI-enabled antibody discovery and optimization, increasing demand for proprietary protein-engineering datasets), and challenges (biosecurity and biosafety concerns, lack of standardized benchmarking across ai protein-engineering platforms) influencing the growth of the AI in protein engineering market.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the AI in protein engineering market.
  • Market Development: Comprehensive information on lucrative emerging markets, offerings, AI tools, applications, protein types, protein engineering processes, end users, and regions.
  • Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the AI in protein engineering market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the AI in protein engineering market like Schrodinger, Inc. (US), XtalPi (China), Dassault Systemes (France), NVIDIA Corporation (US), Generate:Biomedicines (US), Absci Corp. (US), Insilico Medicine (US), Isomorphic Labs (UK), among others.
Show more
Product Code: HIT 10630

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
    • 1.3.2 INCLUSIONS & EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS

2 EXECUTIVE SUMMARY

  • 2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
  • 2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS
  • 2.3 DISRUPTIVE TRENDS SHAPING THE MARKET
  • 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
  • 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

  • 3.1 AI IN PROTEIN ENGINEERING MARKET OVERVIEW
  • 3.2 AI IN PROTEIN ENGINEERING MARKET, BY APPLICATION & COUNTRY
  • 3.3 AI IN PROTEIN ENGINEERING MARKET: GEOGRAPHIC SNAPSHOT

4 MARKET OVERVIEW

  • 4.1 INTRODUCTION
  • 4.2 MARKET DYNAMICS
    • 4.2.1 DRIVERS
      • 4.2.1.1 Increasing adoption of generative AI and protein foundation models
      • 4.2.1.2 Rising demand for next-generation biologics and engineered proteins
      • 4.2.1.3 Increasing availability of protein sequence, structure, and experimental datasets
    • 4.2.2 RESTRAINTS
      • 4.2.2.1 Limited availability of high-quality experimentally validated protein data
      • 4.2.2.2 High cost and complexity of experimental validation
    • 4.2.3 OPPORTUNITIES
      • 4.2.3.1 Expansion of AI-designed de novo proteins
      • 4.2.3.2 Growth of AI-enabled antibody discovery and optimization
      • 4.2.3.3 Increasing demand for proprietary protein-engineering datasets
    • 4.2.4 CHALLENGES
      • 4.2.4.1 Biosecurity and biosafety concerns
      • 4.2.4.2 Lack of standardized benchmarking across AI protein-engineering platforms
  • 4.3 UNMET NEEDS AND WHITE SPACES
  • 4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
  • 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

  • 5.1 INDUSTRY TRENDS IN GLOBAL AI IN PROTEIN ENGINEERING MARKET
  • 5.2 PORTER'S FIVE FORCES ANALYSIS
    • 5.2.1 BARGAINING POWER OF SUPPLIERS
    • 5.2.2 BARGAINING POWER OF BUYERS
    • 5.2.3 THREAT OF SUBSTITUTES
    • 5.2.4 THREAT OF NEW ENTRANTS
    • 5.2.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.3 MACROECONOMIC INDICATORS
    • 5.3.1 INTRODUCTION
    • 5.3.2 GDP TRENDS AND FORECAST
    • 5.3.3 TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY
  • 5.4 VALUE CHAIN ANALYSIS
    • 5.4.1 RESEARCH & PRODUCT DEVELOPMENT
    • 5.4.2 DATA INPUTS & COMPUTATIONAL INFRASTRUCTURE
    • 5.4.3 AI MODEL & PLATFORM DEVELOPMENT
    • 5.4.4 PLATFORM DEPLOYMENT & INTEGRATION
    • 5.4.5 MARKETING AND SALES
    • 5.4.6 POST-SALE SERVICES
  • 5.5 ECOSYSTEM ANALYSIS
  • 5.6 PRICING ANALYSIS
    • 5.6.1 INDICATIVE PRICE FOR AI IN PROTEIN ENGINEERING MARKET, BY OFFERING (2025)
    • 5.6.2 INDICATIVE PRICE FOR AI IN PROTEIN ENGINEERING MARKET, BY REGION (2025)
  • 5.7 KEY CONFERENCES AND EVENTS, 2026-2027
  • 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • 5.9 INVESTMENT AND FUNDING SCENARIO
  • 5.10 CASE STUDY ANALYSIS
  • 5.11 IMPACT OF 2025 US TARIFF - AI IN PROTEIN ENGINEERING MARKET
    • 5.11.1 INTRODUCTION
    • 5.11.2 KEY TARIFF RATES
    • 5.11.3 PRICE IMPACT ANALYSIS
    • 5.11.4 IMPACT ON COUNTRY/REGION
      • 5.11.4.1 US
      • 5.11.4.2 Europe
      • 5.11.4.3 Asia Pacific
    • 5.11.5 IMPACT ON END USERS
      • 5.11.5.1 Pharmaceutical & biotechnology companies
      • 5.11.5.2 Academic & research institutes
      • 5.11.5.3 Contract research organizations
      • 5.11.5.4 Industrial biotechnology companies
      • 5.11.5.5 Other end users

6 STRATEGIC DISRUPTION THROUGH TECHNOLOGY, PATENTS, DIGITAL, AND AI ADOPTION

  • 6.1 KEY EMERGING TECHNOLOGIES
    • 6.1.1 GENERATIVE AI FOR PROTEIN DESIGN
    • 6.1.2 PROTEIN LANGUAGE MODELS (PLMS)
    • 6.1.3 STRUCTURE-BASED AI FOR PROTEIN ENGINEERING
  • 6.2 COMPLEMENTARY TECHNOLOGIES
    • 6.2.1 HIGH-PERFORMANCE COMPUTING (HPC) AND CLOUD COMPUTING
    • 6.2.2 LABORATORY AUTOMATION AND HIGH-THROUGHPUT SCREENING
  • 6.3 ADJACENT TECHNOLOGIES
    • 6.3.1 COMPUTATIONAL CHEMISTRY AND MOLECULAR SIMULATION
    • 6.3.2 BIOINFORMATICS AND BIOLOGICAL DATA ANALYTICS
  • 6.4 TECHNOLOGY/PRODUCT ROADMAP
  • 6.5 PATENT ANALYSIS
    • 6.5.1 PATENT PUBLICATION TRENDS FOR AI IN PROTEIN ENGINEERING MARKET
    • 6.5.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
  • 6.6 FUTURE APPLICATIONS
    • 6.6.1 AI-ENABLED INTELLIGENT PROTEIN DESIGN AND PREDICTION
    • 6.6.2 AI-DRIVEN AUTOMATED PROTEIN ENGINEERING AND DESIGN-BUILD- TEST-LEARN
    • 6.6.3 AI-ENABLED PERSONALIZED AND FUNCTION-SPECIFIC PROTEIN ENGINEERING

7 REGULATORY LANDSCAPE

  • 7.1 REGIONAL REGULATIONS AND COMPLIANCE
    • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, & OTHER ORGANIZATIONS
    • 7.1.2 REGULATORY FRAMEWORK
      • 7.1.2.1 North America
      • 7.1.2.2 Europe
      • 7.1.2.3 ASIA PACIFIC
      • 7.1.2.4 LATIN AMERICA
      • 7.1.2.5 Middle East & Africa
    • 7.1.3 INDUSTRY STANDARDS

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

  • 8.1 INTRODUCTION
  • 8.2 DECISION-MAKING PROCESS
  • 8.3 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
    • 8.3.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 8.3.2 BUYING CRITERIA
  • 8.4 ADOPTION BARRIERS & INTERNAL CHALLENGES
  • 8.5 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
    • 8.5.1 UNMET NEEDS
    • 8.5.2 END USER EXPECTATIONS
  • 8.6 MARKET PROFITABILITY

9 AI IN PROTEIN ENGINEERING MARKET, BY OFFERING

  • 9.1 INTRODUCTION
  • 9.2 SOFTWARE/PLATFORMS
    • 9.2.1 NICHE POINT SOLUTIONS
      • 9.2.1.1 Specialized AI platforms expand protein engineering beyond end-to-end workflows
    • 9.2.2 END-TO-END SOLUTIONS
      • 9.2.2.1 Integrated AI platforms enable multi-stage protein engineering and accelerate candidate development
  • 9.3 SERVICES
    • 9.3.1 CONSULTING & ADVISORY SERVICES
      • 9.3.1.1 Increasing complexity of AI adoption creates demand for protein engineering strategy and technical expertise
    • 9.3.2 IMPLEMENTATION & INTEGRATION SERVICES
      • 9.3.2.1 Integration complexity and data compatibility shape adoption of AI protein engineering solutions
    • 9.3.3 TRAINING & SUPPORT SERVICES
      • 9.3.3.1 Specialized skills gaps and evolving AI technologies sustain demand for training & support

10 AI IN PROTEIN ENGINEERING MARKET, BY AI TOOL

  • 10.1 INTRODUCTION
  • 10.2 MACHINE LEARNING & DEEP LEARNING
    • 10.2.1 FOUNDATIONAL NEURAL ARCHITECTURES UNDERPIN MODERN PROTEIN ENGINEERING WORKFLOWS
  • 10.3 PROTEIN LANGUAGE MODELS
    • 10.3.1 EVOLUTION-SCALE SEQUENCE MODELS ENABLE PREDICTION AND GENERATION WITHOUT STRUCTURAL INPUTS
  • 10.4 GENERATIVE AI
    • 10.4.1 GENERATIVE MODELS MOVE ANTIBODY AND BINDER DESIGN FROM SCREENING TO PROGRAMMABLE DESIGN
  • 10.5 STRUCTURE-BASED AI
    • 10.5.1 ACCURATE COMPLEX PREDICTION SUPPORTS EPITOPE-SPECIFIC DESIGN AND AFFINITY ESTIMATION
  • 10.6 OTHER TOOLS
    • 10.6.1 ACTIVE LEARNING, BAYESIAN OPTIMIZATION, AND LAB-IN-THE-LOOP PLATFORMS COMPLEMENT CORE MODEL CLASSES

11 AI IN PROTEIN ENGINEERING MARKET, BY APPLICATION

  • 11.1 INTRODUCTION
  • 11.2 NEXT-GENERATION BIOLOGICS
    • 11.2.1 THERAPEUTIC PROTEIN ENGINEERING
      • 11.2.1.1 AI-optimized antibodies and engineered proteins move into late-stage development
    • 11.2.2 MULTISPECIFIC & BISPECIFIC PROTEIN ENGINEERING
      • 11.2.2.1 Dual-targeting formats attract record licensing investment as engineering platforms mature
    • 11.2.3 CYTOKINE & GROWTH FACTOR ENGINEERING
      • 11.2.3.1 Redesigned cytokines aim to separate therapeutic benefit from systemic toxicity
    • 11.2.4 PROTEIN BINDER ENGINEERING
      • 11.2.4.1 De novo binder design reaches double-digit to near-complete experimental hit rates
    • 11.2.5 OTHER NEXT-GENERATION BIOLOGICS
      • 11.2.5.1 Antibody-drug conjugates, scaffold fusions, and novel formats broaden engineering toolkits
  • 11.3 MOLECULAR GLUES
  • 11.4 DATA GENERATION
  • 11.5 ANTIBODY DISCOVERY & OPTIMIZATION
    • 11.5.1 ANTIBODY DISCOVERY
      • 11.5.1.1 Generative design reduces dependence on immunization and library screening
    • 11.5.2 ANTIBODY AFFINITY OPTIMIZATION
      • 11.5.2.1 Computational lead optimization improves potency and dosing convenience
    • 11.5.3 ANTIBODY SPECIFICITY & CROSS-REACTIVITY OPTIMIZATION
      • 11.5.3.1 Atomic-level design enables selective binding and controlled species cross-reactivity
    • 11.5.4 ANTIBODY DEVELOPABILITY OPTIMIZATION
      • 11.5.4.1 Early developability screening reduces late-stage attrition risk
    • 11.5.5 BISPECIFIC & MULTISPECIFIC ANTIBODY ENGINEERING
      • 11.5.5.1 Maturing formats and design platforms extend beyond oncology T-Cell engagers
    • 11.5.6 OTHER ANTIBODY ENGINEERING
      • 11.5.6.1 Fc modification, half-life extension, and delivery formats broaden antibody differentiation
  • 11.6 ENZYME ENGINEERING
  • 11.7 DE NOVO PROTEIN DESIGN
  • 11.8 PROTEIN STABILITY & DEVELOPABILITY OPTIMIZATION
  • 11.9 OTHER APPLICATIONS

12 AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE

  • 12.1 INTRODUCTION
  • 12.2 ANTIBODIES
    • 12.2.1 AI-DRIVEN ANTIBODY DESIGN AND OPTIMIZATION ACCELERATE NEXT-GENERATION BIOLOGICS DEVELOPMENT
  • 12.3 ENZYMES
    • 12.3.1 AI-POWERED ENZYME ENGINEERING EXPANDS APPLICATIONS ACROSS INDUSTRIAL BIOCATALYSIS
  • 12.4 CYTOKINES & GROWTH FACTORS
    • 12.4.1 ADVANCING PRECISION ENGINEERING OF CYTOKINES AND GROWTH FACTORS
  • 12.5 PEPTIDES
    • 12.5.1 AI ADDRESSES COMPLEXITY IN PEPTIDE SEQUENCE DESIGN AND FUNCTIONAL OPTIMIZATION
  • 12.6 FUSION PROTEINS
    • 12.6.1 AI IMPROVES MULTI-DOMAIN DESIGN OF FUSION PROTEINS
  • 12.7 MINIPROTEIN
    • 12.7.1 DE NOVO MINIPROTEIN DESIGN OPENS NEW OPPORTUNITIES FOR PRECISION BIOLOGICS
  • 12.8 OTHER PROTEINS
    • 12.8.1 EMERGING PROTEIN MODALITIES CREATE NEW OPPORTUNITIES FOR AI-ENABLED ENGINEERING

13 AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN ENGINEERING PROCESS

  • 13.1 INTRODUCTION
  • 13.2 PROTEIN DISCOVERY
    • 13.2.1 EXPANDING SEQUENCE AND STRUCTURE DATABASES ACCELERATE TARGET AND STARTING-POINT IDENTIFICATION
  • 13.3 PROTEIN DESIGN
    • 13.3.1 OPEN GENERATIVE MODELS MOVE DE NOVO DESIGN FROM PROOF OF CONCEPT TO BROAD EXPERIMENTAL VALIDATION
  • 13.4 PROTEIN OPTIMIZATION
    • 13.4.1 MACHINE LEARNING-GUIDED OPTIMIZATION IMPROVES AFFINITY, STABILITY, AND MANUFACTURABILITY ACROSS ITERATIVE CYCLES
  • 13.5 PROTEIN CHARACTERIZATION
    • 13.5.1 HIGHER-RESOLUTION STRUCTURAL AND BIOPHYSICAL ANALYSIS ANCHORS COMPUTATIONAL PREDICTIONS IN EXPERIMENTAL REALITY
  • 13.6 EXPERIMENTAL VALIDATION
    • 13.6.1 CLOUD LABS, PUBLIC COMPETITIONS, AND LAB-IN-THE-LOOP PLATFORMS SCALE WET-LAB TESTING

14 AI IN PROTEIN ENGINEERING MARKET, BY END USER

  • 14.1 INTRODUCTION
  • 14.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 14.2.1 HIGH R&D INVESTMENTS AND GROWING AI INTEGRATION ACCELERATE PROTEIN ENGINEERING ADOPTION
  • 14.3 ACADEMIC & RESEARCH INSTITUTES
    • 14.3.1 ADVANCING PROTEIN SCIENCE THROUGH AI-ENABLED RESEARCH AND COMPUTATIONAL DESIGN
  • 14.4 CONTRACT RESEARCH ORGANIZATIONS
    • 14.4.1 AI HELPS CROS DIFFERENTIATE PROTEIN ENGINEERING SERVICES AND EXPAND OUTSOURCED DISCOVERY CAPABILITIES
  • 14.5 INDUSTRIAL BIOTECHNOLOGY COMPANIES
    • 14.5.1 AI-DRIVEN BIOCATALYST DEVELOPMENT ACCELERATES ADOPTION IN INDUSTRIAL BIOTECHNOLOGY
  • 14.6 OTHER END USERS
    • 14.6.1 EXPANSION OF AI-ENABLED PROTEIN ENGINEERING ACROSS DIVERSE APPLICATIONS TO BOOST SEGMENT

15 AI IN PROTEIN ENGINEERING MARKET, BY REGION

  • 15.1 INTRODUCTION
  • 15.2 NORTH AMERICA
    • 15.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 15.2.2 US
      • 15.2.2.1 AI-driven protein design and strong biopharmaceutical R&D support market growth
    • 15.2.3 CANADA
      • 15.2.3.1 Government support for AI innovation and biomanufacturing strengthens market growth
  • 15.3 EUROPE
    • 15.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 15.3.2 GERMANY
      • 15.3.2.1 Strong pharmaceutical research base and AI innovation drive protein engineering adoption
    • 15.3.3 FRANCE
      • 15.3.3.1 Biopharma innovation and research commercialization support market expansion
    • 15.3.4 UK
      • 15.3.4.1 Regulatory innovation and AI-driven drug discovery accelerate adoption
    • 15.3.5 ITALY
      • 15.3.5.1 Pharmaceutical manufacturing strength and research modernization create opportunities
    • 15.3.6 SPAIN
      • 15.3.6.1 Strong pharmaceutical R&D and biopharma ecosystem support market growth
    • 15.3.7 REST OF EUROPE
  • 15.4 ASIA PACIFIC
    • 15.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 15.4.2 CHINA
      • 15.4.2.1 AI-driven protein engineering and biologics innovation reshape pharmaceutical development
    • 15.4.3 JAPAN
      • 15.4.3.1 Demographic pressures and AI innovation drive protein engineering adoption
    • 15.4.4 INDIA
      • 15.4.4.1 Cost-efficient innovation and biotechnology expansion support growth
    • 15.4.5 AUSTRALIA
      • 15.4.5.1 Translational research ecosystem supports AI-enabled protein engineering
    • 15.4.6 SOUTH KOREA
      • 15.4.6.1 Biotechnology Expansion and AI investments support protein engineering adoption
    • 15.4.7 REST OF ASIA PACIFIC
  • 15.5 LATIN AMERICA
    • 15.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    • 15.5.2 BRAZIL
      • 15.5.2.1 Leading regional pharmaceutical research activity supports market growth
    • 15.5.3 MEXICO
      • 15.5.3.1 Pharmaceutical manufacturing base and growing R&D activity support AI adoption
    • 15.5.4 REST OF LATIN AMERICA
  • 15.6 MIDDLE EAST & AFRICA
    • 15.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
    • 15.6.2 GCC COUNTRIES
      • 15.6.2.1 Healthcare transformation and biotechnology investments support market growth
      • 15.6.2.2 Saudi Arabia
        • 15.6.2.2.1 Vision 2030 investments accelerate biotechnology and AI-enabled protein engineering
      • 15.6.2.3 UAE
        • 15.6.2.3.1 Healthcare innovation and biotechnology initiatives support market growth
      • 15.6.2.4 Other GCC countries
    • 15.6.3 SOUTH AFRICA
      • 15.6.3.1 Expanding biotechnology and research capabilities support market growth
    • 15.6.4 REST OF MIDDLE EAST & AFRICA

16 COMPETITIVE LANDSCAPE

  • 16.1 OVERVIEW
  • 16.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 16.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN AI IN PROTEIN ENGINEERING MARKET
  • 16.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
  • 16.4 MARKET SHARE ANALYSIS, 2025
  • 16.5 BRAND COMPARISON
  • 16.6 VALUATION & FINANCIAL METRICS
    • 16.6.1 FINANCIAL METRICS
    • 16.6.2 COMPANY VALUATION
  • 16.7 COMPANY EVALUATION MATRIX, KEY PLAYERS (2025)
    • 16.7.1 STARS
    • 16.7.2 EMERGING LEADERS
    • 16.7.3 PERVASIVE PLAYERS
    • 16.7.4 PARTICIPANTS
    • 16.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
      • 16.7.5.1 Company footprint
      • 16.7.5.2 Region footprint
      • 16.7.5.3 Offering footprint
      • 16.7.5.4 Application footprint
      • 16.7.5.5 AI tool footprint
      • 16.7.5.6 End user footprint
  • 16.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
    • 16.8.1 PROGRESSIVE COMPANIES
    • 16.8.2 RESPONSIVE COMPANIES
    • 16.8.3 DYNAMIC COMPANIES
    • 16.8.4 STARTING BLOCKS
    • 16.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
      • 16.8.5.1 Detailed list of key startups/SMEs
      • 16.8.5.2 Competitive benchmarking of startups/SMEs
  • 16.9 COMPETITIVE SCENARIO
    • 16.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS
    • 16.9.2 DEALS

17 COMPANY PROFILES

  • 17.1 KEY PLAYERS
    • 17.1.1 SCHRODINGER, INC.
      • 17.1.1.1 Business overview
      • 17.1.1.2 Products offered
      • 17.1.1.3 Recent developments
        • 17.1.1.3.1 Product enhancements
        • 17.1.1.3.2 Deals
      • 17.1.1.4 MnM view
        • 17.1.1.4.1 Key strengths
        • 17.1.1.4.2 Strategic choices
        • 17.1.1.4.3 Weaknesses and competitive threats
    • 17.1.2 XTALPI
      • 17.1.2.1 Business overview
      • 17.1.2.2 Products offered
      • 17.1.2.3 Recent developments
        • 17.1.2.3.1 Deals
      • 17.1.2.4 MnM view
        • 17.1.2.4.1 Key strengths
        • 17.1.2.4.2 Strategic choices
        • 17.1.2.4.3 Weaknesses and competitive threats
    • 17.1.3 DASSAULT SYSTEMES
      • 17.1.3.1 Business overview
      • 17.1.3.2 Products Offered
      • 17.1.3.3 Recent developments
        • 17.1.3.3.1 Product launches/enhancements
        • 17.1.3.3.2 Deals
      • 17.1.3.4 MnM view
        • 17.1.3.4.1 Key strengths
        • 17.1.3.4.2 Strategic choices
        • 17.1.3.4.3 Weaknesses and competitive threats
    • 17.1.4 NVIDIA CORPORATION
      • 17.1.4.1 Business overview
      • 17.1.4.2 Products/Solutions offered
      • 17.1.4.3 Recent developments
        • 17.1.4.3.1 Product launches/enhancements
        • 17.1.4.3.2 Deals
      • 17.1.4.4 MnM view
        • 17.1.4.4.1 Key strengths
        • 17.1.4.4.2 Strategic choices
        • 17.1.4.4.3 Weaknesses and competitive threats
    • 17.1.5 GENERATE:BIOMEDICINES
      • 17.1.5.1 Business overview
      • 17.1.5.2 Products offered
      • 17.1.5.3 Recent developments
        • 17.1.5.3.1 Product enhancements
        • 17.1.5.3.2 Deals
      • 17.1.5.4 MnM view
        • 17.1.5.4.1 Key strengths
        • 17.1.5.4.2 Strategic choices
        • 17.1.5.4.3 Weaknesses and competitive threats
    • 17.1.6 ABSCI CORP.
      • 17.1.6.1 Business overview
      • 17.1.6.2 Products Offered
      • 17.1.6.3 Recent developments
        • 17.1.6.3.1 Deals
      • 17.1.6.4 MnM view
        • 17.1.6.4.1 Key strengths
        • 17.1.6.4.2 Strategic choices
        • 17.1.6.4.3 Weaknesses and competitive threats
    • 17.1.7 INSILICO MEDICINE
      • 17.1.7.1 Business overview
      • 17.1.7.2 Products/Solutions offered
      • 17.1.7.3 Recent developments
        • 17.1.7.3.1 Product launches/enhancements
        • 17.1.7.3.2 Deals
      • 17.1.7.4 MnM view
        • 17.1.7.4.1 Key strengths
        • 17.1.7.4.2 Strategic choices
        • 17.1.7.4.3 Weaknesses and competitive threats
    • 17.1.8 CRADLE
      • 17.1.8.1 Business overview
      • 17.1.8.2 Products offered
      • 17.1.8.3 Recent developments
        • 17.1.8.3.1 Deals
        • 17.1.8.3.2 Other developments
    • 17.1.9 A-ALPHA BIO, INC.
      • 17.1.9.1 Business overview
      • 17.1.9.2 Products offered
      • 17.1.9.3 Recent developments
        • 17.1.9.3.1 Product launches
        • 17.1.9.3.2 Deals
        • 17.1.9.3.3 Other developments
    • 17.1.10 ISOMORPHIC LABS
      • 17.1.10.1 Business overview
      • 17.1.10.2 Products offered
      • 17.1.10.3 Recent developments
        • 17.1.10.3.1 Deals
        • 17.1.10.3.2 Other developments
    • 17.1.11 CHAI DISCOVERY
      • 17.1.11.1 Business overview
      • 17.1.11.2 Products offered
      • 17.1.11.3 Recent developments
        • 17.1.11.3.1 Product launches and approvals
        • 17.1.11.3.2 Deals
        • 17.1.11.3.3 Other developments
    • 17.1.12 EVOLUTIONARYSCALE (BIOHUB)
      • 17.1.12.1 Business overview
      • 17.1.12.2 Products offered
      • 17.1.12.3 Recent developments
        • 17.1.12.3.1 Product launches and approvals
        • 17.1.12.3.2 Deals
        • 17.1.12.3.3 Other developments
    • 17.1.13 PROFLUENT
      • 17.1.13.1 Business overview
      • 17.1.13.2 Products offered
      • 17.1.13.3 Recent developments
        • 17.1.13.3.1 Deals
        • 17.1.13.3.2 Other developments
    • 17.1.14 BIGHAT BIO
      • 17.1.14.1 Business overview
      • 17.1.14.2 Products offered
      • 17.1.14.3 Recent developments
        • 17.1.14.3.1 Product launches
        • 17.1.14.3.2 Deals
    • 17.1.15 LATENT LABS
      • 17.1.15.1 Business overview
      • 17.1.15.2 Products offered
      • 17.1.15.3 Recent developments
        • 17.1.15.3.1 Product launches
        • 17.1.15.3.2 Deals
        • 17.1.15.3.3 Other developments
    • 17.1.16 BASECAMP RESEARCH
      • 17.1.16.1 Business overview
      • 17.1.16.2 Products offered
      • 17.1.16.3 Recent developments
        • 17.1.16.3.1 Product launches
        • 17.1.16.3.2 Deals
        • 17.1.16.3.3 Other developments
    • 17.1.17 NABLA BIO, INC.
      • 17.1.17.1 Business overview
      • 17.1.17.2 Products offered
      • 17.1.17.3 Recent developments
        • 17.1.17.3.1 Deals
        • 17.1.17.3.2 Other developments
    • 17.1.18 EVOZYNE
      • 17.1.18.1 Business overview
      • 17.1.18.2 Products offered
      • 17.1.18.3 Recent developments
        • 17.1.18.3.1 Deals
        • 17.1.18.3.2 Other developments
    • 17.1.19 LABGENIUS LIMITED
      • 17.1.19.1 Business overview
      • 17.1.19.2 Products offered
      • 17.1.19.3 Recent developments
        • 17.1.19.3.1 Deals
        • 17.1.19.3.2 Other developments
  • 17.2 OTHER PLAYERS
    • 17.2.1 ARZEDA CORPORATION
    • 17.2.2 MENTEN AI
    • 17.2.3 PROTEINQURE
    • 17.2.4 OUTPACE BIO
    • 17.2.5 AI PROTEINS
    • 17.2.6 MONODBIO
    • 17.2.7 BIOMATTER INC.
    • 17.2.8 DIFFUSE BIO

18 RESEARCH METHODOLOGY

  • 18.1 RESEARCH APPROACH
    • 18.1.1 SECONDARY RESEARCH
      • 18.1.1.1 Key data from secondary sources
    • 18.1.2 PRIMARY RESEARCH
      • 18.1.2.1 Primary sources
      • 18.1.2.2 Key data from primary sources
      • 18.1.2.3 Breakdown of primaries
      • 18.1.2.4 Insights from primary experts
  • 18.2 RESEARCH METHODOLOGY DESIGN
  • 18.3 MARKET SIZE ESTIMATION
  • 18.4 MARKET BREAKDOWN DATA TRIANGULATION
  • 18.5 MARKET SHARE ESTIMATION
  • 18.6 STUDY ASSUMPTIONS
  • 18.7 RESEARCH LIMITATIONS
    • 18.7.1 METHODOLOGY-RELATED LIMITATIONS
  • 18.8 RISK ASSESSMENT

19 APPENDIX

  • 19.1 DISCUSSION GUIDE
  • 19.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 19.3 CUSTOMIZATION OPTIONS
  • 19.4 RELATED REPORTS
  • 19.5 AUTHOR DETAILS
Show more
Product Code: HIT 10630

List of Tables

  • TABLE 1 USD EXCHANGE RATES
  • TABLE 2 AI IN PROTEIN ENGINEERING MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 3 AI IN PROTEIN ENGINEERING MARKET: ROLE IN ECOSYSTEM
  • TABLE 4 INDICATIVE PRICE FOR AI IN PROTEIN ENGINEERING MARKET, BY OFFERING (2025)
  • TABLE 5 INDICATIVE PRICE FOR AI IN PROTEIN ENGINEERING MARKET, BY REGION (2025)
  • TABLE 6 AI IN PROTEIN ENGINEERING MARKET: KEY CONFERENCES, 2026-2027
  • TABLE 7 CASE 1: AI-GUIDED ENZYME OPTIMIZATION USING HISTORICAL EXPERIMENTAL DATA
  • TABLE 8 CASE 2: AI-GENERATED PROTEIN DESIGN FOR PRECISION GENE EDITING
  • TABLE 9 CASE 3: COMPUTATIONAL PROTEIN DESIGN FOR AI-DESIGNED PEPTIDE THERAPEUTIC
  • TABLE 10 US ADJUSTED RECIPROCAL TARIFF RATES
  • TABLE 11 JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES FOR AI IN PROTEIN ENGINEERING MARKET
  • TABLE 12 AI IN PROTEIN ENGINEERING MARKET: KEY PATENTS/PATENT APPLICATIONS
  • TABLE 13 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 14 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 15 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 16 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 17 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 18 REGULATORY SCENARIO OF NORTH AMERICA
  • TABLE 19 REGULATORY SCENARIO OF EUROPE
  • TABLE 20 REGULATORY SCENARIO OF ASIA PACIFIC
  • TABLE 21 REGULATORY SCENARIO OF LATIN AMERICA
  • TABLE 22 REGULATORY SCENARIO OF MIDDLE EAST & AFRICA
  • TABLE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP THREE END USERS (%)
  • TABLE 24 KEY BUYING CRITERIA FOR TOP THREE END USERS
  • TABLE 25 UNMET NEEDS IN AI IN PROTEIN ENGINEERING MARKET
  • TABLE 26 END USER EXPECTATIONS IN AI IN PROTEIN ENGINEERING MARKET
  • TABLE 27 AI IN PROTEIN ENGINEERING MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 28 AI IN PROTEIN ENGINEERING MARKET, FOR SOFTWARE/PLATFORMS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 29 AI IN PROTEIN ENGINEERING MARKET, FOR SOFTWARE/PLATFORMS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 30 AI IN PROTEIN ENGINEERING MARKET, FOR NICHE POINT SOLUTIONS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 31 AI IN PROTEIN ENGINEERING MARKET, FOR END-TO-END SOLUTIONS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 32 AI IN PROTEIN ENGINEERING MARKET, FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 33 AI IN PROTEIN ENGINEERING MARKET, FOR SERVICES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 34 AI IN PROTEIN ENGINEERING MARKET, FOR CONSULTING & ADVISORY SERVICES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 35 AI IN PROTEIN ENGINEERING MARKET, FOR IMPLEMENTATION & INTEGRATION SERVICES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 36 AI IN PROTEIN ENGINEERING MARKET, FOR TRAINING & SUPPORT SERVICES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 37 AI IN PROTEIN ENGINEERING MARKET, BY AI TOOL, 2024-2031 (USD MILLION)
  • TABLE 38 AI IN PROTEIN ENGINEERING MARKET FOR MACHINE LEARNING & DEEP LEARNING, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 39 AI IN PROTEIN ENGINEERING MARKET FOR PROTEIN LANGUAGE MODELS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 40 AI IN PROTEIN ENGINEERING MARKET FOR GENERATIVE AI, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 41 AI IN PROTEIN ENGINEERING MARKET FOR STRUCTURE-BASED AI, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 42 AI IN PROTEIN ENGINEERING MARKET FOR OTHER TOOLS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 43 AI IN PROTEIN ENGINEERING MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 44 AI IN PROTEIN ENGINEERING MARKET FOR NEXT-GENERATION BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 45 AI IN PROTEIN ENGINEERING MARKET FOR NEXT-GENERATION BIOLOGICS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 46 AI IN PROTEIN ENGINEERING MARKET FOR THERAPEUTIC PROTEIN ENGINEERING, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 47 AI IN PROTEIN ENGINEERING MARKET FOR MULTISPECIFIC & BISPECIFIC PROTEIN ENGINEERING, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 48 AI IN PROTEIN ENGINEERING MARKET FOR CYTOKINE & GROWTH FACTOR ENGINEERING, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 49 AI IN PROTEIN ENGINEERING MARKET FOR PROTEIN BINDER ENGINEERING, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 50 AI IN PROTEIN ENGINEERING MARKET FOR OTHER NEXT-GENERATION BIOLOGICS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 51 AI IN PROTEIN ENGINEERING MARKET FOR MOLECULAR GLUES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 52 AI IN PROTEIN ENGINEERING MARKET FOR DATA GENERATION, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 53 AI IN PROTEIN ENGINEERING MARKET FOR ANTIBODY DISCOVERY & OPTIMIZATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 54 AI IN PROTEIN ENGINEERING MARKET FOR ANTIBODY DISCOVERY & OPTIMIZATION, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 55 AI IN PROTEIN ENGINEERING MARKET FOR ANTIBODY DISCOVERY, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 56 AI IN PROTEIN ENGINEERING MARKET FOR ANTIBODY AFFINITY OPTIMIZATION, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 57 AI IN PROTEIN ENGINEERING MARKET FOR ANTIBODY SPECIFICITY & CROSS-REACTIVITY OPTIMIZATION, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 58 AI IN PROTEIN ENGINEERING MARKET FOR ANTIBODY DEVELOPABILITY OPTIMIZATION, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 59 AI IN PROTEIN ENGINEERING MARKET FOR BISPECIFIC & MULTISPECIFIC ANTIBODY ENGINEERING, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 60 AI IN PROTEIN ENGINEERING MARKET FOR OTHER ANTIBODY ENGINEERING, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 61 AI IN PROTEIN ENGINEERING MARKET FOR ENZYME ENGINEERING, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 62 AI IN PROTEIN ENGINEERING MARKET FOR DE NOVO PROTEIN DESIGN, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 63 AI IN PROTEIN ENGINEERING MARKET FOR PROTEIN STABILITY & DEVELOPABILITY OPTIMIZATION, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 64 AI IN PROTEIN ENGINEERING MARKET FOR OTHER APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 65 AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE, 2024-2031 (USD MILLION)
  • TABLE 66 AI IN PROTEIN ENGINEERING MARKET FOR ANTIBODIES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 67 AI IN PROTEIN ENGINEERING MARKET FOR ENZYMES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 68 AI IN PROTEIN ENGINEERING MARKET FOR CYTOKINES & GROWTH FACTORS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 69 AI IN PROTEIN ENGINEERING MARKET FOR PEPTIDES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 70 AI IN PROTEIN ENGINEERING MARKET FOR FUSION PROTEINS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 71 AI IN PROTEIN ENGINEERING MARKET FOR MINIPROTEIN, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 72 AI IN PROTEIN ENGINEERING MARKET FOR OTHER PROTEINS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 73 AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN ENGINEERING PROCESS, 2024-2031 (USD MILLION)
  • TABLE 74 AI IN PROTEIN ENGINEERING MARKET FOR PROTEIN DISCOVERY, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 75 AI IN PROTEIN ENGINEERING MARKET FOR PROTEIN DESIGN, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 76 AI IN PROTEIN ENGINEERING MARKET FOR PROTEIN OPTIMIZATION, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 77 AI IN PROTEIN ENGINEERING MARKET FOR PROTEIN CHARACTERIZATION, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 78 AI IN PROTEIN ENGINEERING MARKET FOR EXPERIMENTAL VALIDATION, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 79 AI IN PROTEIN ENGINEERING MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 80 AI IN PROTEIN ENGINEERING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 81 AI IN PROTEIN ENGINEERING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 82 AI IN PROTEIN ENGINEERING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 83 AI IN PROTEIN ENGINEERING MARKET FOR INDUSTRIAL BIOTECHNOLOGY COMPANIES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 84 AI IN PROTEIN ENGINEERING MARKET FOR OTHER END USERS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 85 AI IN PROTEIN ENGINEERING MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 86 NORTH AMERICA AI IN PROTEIN ENGINEERING MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 87 NORTH AMERICA: AI IN PROTEIN ENGINEERING MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 88 NORTH AMERICA: AI IN PROTEIN ENGINEERING MARKET FOR SOFTWARE/PLATFORMS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 89 NORTH AMERICA: AI IN PROTEIN ENGINEERING MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 90 NORTH AMERICA: AI IN PROTEIN ENGINEERING MARKET, BY AI TOOL, 2024-2031 (USD MILLION)
  • TABLE 91 NORTH AMERICA: AI IN PROTEIN ENGINEERING MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 92 NORTH AMERICA: AI IN PROTEIN ENGINEERING MARKET FOR NEXT-GENERATION BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 93 NORTH AMERICA: AI IN PROTEIN ENGINEERING MARKET FOR ANTIBODY DISCOVERY & OPTIMIZATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 94 NORTH AMERICA: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE, 2024-2031 (USD MILLION)
  • TABLE 95 NORTH AMERICA: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN ENGINEERING PROCESS, 2024-2031 (USD MILLION)
  • TABLE 96 NORTH AMERICA: AI IN PROTEIN ENGINEERING MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 97 US: AI IN PROTEIN ENGINEERING MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 98 US: AI IN PROTEIN ENGINEERING MARKET FOR SOFTWARE/PLATFORMS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 99 US: AI IN PROTEIN ENGINEERING MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 100 US: AI IN PROTEIN ENGINEERING MARKET, BY AI TOOL, 2024-2031 (USD MILLION)
  • TABLE 101 US: AI IN PROTEIN ENGINEERING MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 102 US: AI IN PROTEIN ENGINEERING MARKET FOR NEXT-GENERATION BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 103 US: AI IN PROTEIN ENGINEERING MARKET FOR ANTIBODY DISCOVERY & OPTIMIZATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 104 US: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE, 2024-2031 (USD MILLION)
  • TABLE 105 US: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN ENGINEERING PROCESS, 2024-2031 (USD MILLION)
  • TABLE 106 US: AI IN PROTEIN ENGINEERING MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 107 CANADA: AI IN PROTEIN ENGINEERING MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 108 CANADA: AI IN PROTEIN ENGINEERING MARKET FOR SOFTWARE/PLATFORMS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 109 CANADA: AI IN PROTEIN ENGINEERING MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 110 CANADA: AI IN PROTEIN ENGINEERING MARKET, BY AI TOOL, 2024-2031 (USD MILLION)
  • TABLE 111 CANADA: AI IN PROTEIN ENGINEERING MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 112 CANADA: AI IN PROTEIN ENGINEERING MARKET FOR NEXT-GENERATION BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 113 CANADA: AI IN PROTEIN ENGINEERING MARKET FOR ANTIBODY DISCOVERY & OPTIMIZATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 114 CANADA: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE, 2024-2031 (USD MILLION)
  • TABLE 115 CANADA: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN ENGINEERING PROCESS, 2024-2031 (USD MILLION)
  • TABLE 116 CANADA: AI IN PROTEIN ENGINEERING MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 117 EUROPE: AI IN PROTEIN ENGINEERING MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 118 EUROPE: AI IN PROTEIN ENGINEERING MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 119 EUROPE: AI IN PROTEIN ENGINEERING MARKET FOR SOFTWARE/PLATFORMS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 120 EUROPE: AI IN PROTEIN ENGINEERING MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 121 EUROPE: AI IN PROTEIN ENGINEERING MARKET, BY AI TOOL, 2024-2031 (USD MILLION)
  • TABLE 122 EUROPE: AI IN PROTEIN ENGINEERING MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 123 EUROPE: AI IN PROTEIN ENGINEERING MARKET FOR NEXT-GENERATION BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 124 EUROPE: AI IN PROTEIN ENGINEERING MARKET FOR ANTIBODY DISCOVERY & OPTIMIZATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 125 EUROPE: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE, 2024-2031 (USD MILLION)
  • TABLE 126 EUROPE: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN ENGINEERING PROCESS, 2024-2031 (USD MILLION)
  • TABLE 127 EUROPE: AI IN PROTEIN ENGINEERING MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 128 GERMANY: AI IN PROTEIN ENGINEERING MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 129 GERMANY: AI IN PROTEIN ENGINEERING MARKET FOR SOFTWARE/PLATFORMS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 130 GERMANY: AI IN PROTEIN ENGINEERING MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 131 GERMANY: AI IN PROTEIN ENGINEERING MARKET, BY AI TOOL, 2024-2031 (USD MILLION)
  • TABLE 132 GERMANY: AI IN PROTEIN ENGINEERING MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 133 GERMANY: AI IN PROTEIN ENGINEERING MARKET FOR NEXT-GENERATION BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 134 GERMANY: AI IN PROTEIN ENGINEERING MARKET FOR ANTIBODY DISCOVERY & OPTIMIZATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 135 GERMANY: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE, 2024-2031 (USD MILLION)
  • TABLE 136 GERMANY: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN ENGINEERING PROCESS, 2024-2031 (USD MILLION)
  • TABLE 137 GERMANY: AI IN PROTEIN ENGINEERING MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 138 FRANCE: AI IN PROTEIN ENGINEERING MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 139 FRANCE: AI IN PROTEIN ENGINEERING MARKET FOR SOFTWARE/PLATFORMS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 140 FRANCE: AI IN PROTEIN ENGINEERING MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 141 FRANCE: AI IN PROTEIN ENGINEERING MARKET, BY AI TOOL, 2024-2031 (USD MILLION)
  • TABLE 142 FRANCE: AI IN PROTEIN ENGINEERING MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 143 FRANCE: AI IN PROTEIN ENGINEERING MARKET FOR NEXT-GENERATION BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 144 FRANCE: AI IN PROTEIN ENGINEERING MARKET FOR ANTIBODY DISCOVERY & OPTIMIZATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 145 FRANCE: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE, 2024-2031 (USD MILLION)
  • TABLE 146 FRANCE: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN ENGINEERING PROCESS, 2024-2031 (USD MILLION)
  • TABLE 147 FRANCE: AI IN PROTEIN ENGINEERING MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 148 UK: AI IN PROTEIN ENGINEERING MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 149 UK: AI IN PROTEIN ENGINEERING MARKET FOR SOFTWARE/PLATFORMS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 150 UK: AI IN PROTEIN ENGINEERING MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 151 UK: AI IN PROTEIN ENGINEERING MARKET, BY AI TOOL, 2024-2031 (USD MILLION)
  • TABLE 152 UK: AI IN PROTEIN ENGINEERING MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 153 UK: AI IN PROTEIN ENGINEERING MARKET FOR NEXT-GENERATION BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 154 UK: AI IN PROTEIN ENGINEERING MARKET FOR ANTIBODY DISCOVERY & OPTIMIZATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 155 UK: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE, 2024-2031 (USD MILLION)
  • TABLE 156 UK: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN ENGINEERING PROCESS, 2024-2031 (USD MILLION)
  • TABLE 157 UK: AI IN PROTEIN ENGINEERING MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 158 ITALY: AI IN PROTEIN ENGINEERING MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 159 ITALY: AI IN PROTEIN ENGINEERING MARKET FOR SOFTWARE/PLATFORMS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 160 ITALY: AI IN PROTEIN ENGINEERING MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 161 ITALY: AI IN PROTEIN ENGINEERING MARKET, BY AI TOOL, 2024-2031 (USD MILLION)
  • TABLE 162 ITALY: AI IN PROTEIN ENGINEERING MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 163 ITALY: AI IN PROTEIN ENGINEERING MARKET FOR NEXT-GENERATION BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 164 ITALY: AI IN PROTEIN ENGINEERING MARKET FOR ANTIBODY DISCOVERY & OPTIMIZATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 165 ITALY: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE, 2024-2031 (USD MILLION)
  • TABLE 166 ITALY: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN ENGINEERING PROCESS, 2024-2031 (USD MILLION)
  • TABLE 167 ITALY: AI IN PROTEIN ENGINEERING MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 168 SPAIN: AI IN PROTEIN ENGINEERING MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 169 SPAIN: AI IN PROTEIN ENGINEERING MARKET FOR SOFTWARE/PLATFORMS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 170 SPAIN: AI IN PROTEIN ENGINEERING MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 171 SPAIN: AI IN PROTEIN ENGINEERING MARKET, BY AI TOOL, 2024-2031 (USD MILLION)
  • TABLE 172 SPAIN: AI IN PROTEIN ENGINEERING MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 173 SPAIN: AI IN PROTEIN ENGINEERING MARKET FOR NEXT-GENERATION BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 174 SPAIN: AI IN PROTEIN ENGINEERING MARKET FOR ANTIBODY DISCOVERY & OPTIMIZATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 175 SPAIN: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE, 2024-2031 (USD MILLION)
  • TABLE 176 SPAIN: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN ENGINEERING PROCESS, 2024-2031 (USD MILLION)
  • TABLE 177 SPAIN: AI IN PROTEIN ENGINEERING MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 178 REST OF EUROPE: AI IN PROTEIN ENGINEERING MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 179 REST OF EUROPE: AI IN PROTEIN ENGINEERING MARKET FOR SOFTWARE/PLATFORMS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 180 REST OF EUROPE: AI IN PROTEIN ENGINEERING MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 181 REST OF EUROPE: AI IN PROTEIN ENGINEERING MARKET, BY AI TOOL, 2024-2031 (USD MILLION)
  • TABLE 182 REST OF EUROPE: AI IN PROTEIN ENGINEERING MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 183 REST OF EUROPE: AI IN PROTEIN ENGINEERING MARKET FOR NEXT-GENERATION BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 184 REST OF EUROPE: AI IN PROTEIN ENGINEERING MARKET FOR ANTIBODY DISCOVERY & OPTIMIZATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 185 REST OF EUROPE: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE, 2024-2031 (USD MILLION)
  • TABLE 186 REST OF EUROPE: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN ENGINEERING PROCESS, 2024-2031 (USD MILLION)
  • TABLE 187 REST OF EUROPE: AI IN PROTEIN ENGINEERING MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 188 ASIA PACIFIC: AI IN PROTEIN ENGINEERING MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 189 ASIA PACIFIC: AI IN PROTEIN ENGINEERING MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 190 ASIA PACIFIC: AI IN PROTEIN ENGINEERING MARKET FOR SOFTWARE/PLATFORMS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 191 ASIA PACIFIC: AI IN PROTEIN ENGINEERING MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 192 ASIA PACIFIC: AI IN PROTEIN ENGINEERING MARKET, BY AI TOOL, 2024-2031 (USD MILLION)
  • TABLE 193 ASIA PACIFIC: AI IN PROTEIN ENGINEERING MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 194 ASIA PACIFIC: AI IN PROTEIN ENGINEERING MARKET FOR NEXT-GENERATION BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 195 ASIA PACIFIC: AI IN PROTEIN ENGINEERING MARKET FOR ANTIBODY DISCOVERY & OPTIMIZATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 196 ASIA PACIFIC: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE, 2024-2031 (USD MILLION)
  • TABLE 197 ASIA PACIFIC: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN ENGINEERING PROCESS, 2024-2031 (USD MILLION)
  • TABLE 198 ASIA PACIFIC: AI IN PROTEIN ENGINEERING MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 199 CHINA: AI IN PROTEIN ENGINEERING MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 200 CHINA: AI IN PROTEIN ENGINEERING MARKET FOR SOFTWARE/PLATFORMS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 201 CHINA: AI IN PROTEIN ENGINEERING MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 202 CHINA: AI IN PROTEIN ENGINEERING MARKET, BY AI TOOL, 2024-2031 (USD MILLION)
  • TABLE 203 CHINA: AI IN PROTEIN ENGINEERING MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 204 CHINA: AI IN PROTEIN ENGINEERING MARKET FOR NEXT-GENERATION BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 205 CHINA: AI IN PROTEIN ENGINEERING MARKET FOR ANTIBODY DISCOVERY & OPTIMIZATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 206 CHINA: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE, 2024-2031 (USD MILLION)
  • TABLE 207 CHINA: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN ENGINEERING PROCESS, 2024-2031 (USD MILLION)
  • TABLE 208 CHINA: AI IN PROTEIN ENGINEERING MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 209 JAPAN: AI IN PROTEIN ENGINEERING MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 210 JAPAN: AI IN PROTEIN ENGINEERING MARKET FOR SOFTWARE/PLATFORMS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 211 JAPAN: AI IN PROTEIN ENGINEERING MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 212 JAPAN: AI IN PROTEIN ENGINEERING MARKET, BY AI TOOL, 2024-2031 (USD MILLION)
  • TABLE 213 JAPAN: AI IN PROTEIN ENGINEERING MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 214 JAPAN: AI IN PROTEIN ENGINEERING MARKET FOR NEXT-GENERATION BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 215 JAPAN: AI IN PROTEIN ENGINEERING MARKET FOR ANTIBODY DISCOVERY & OPTIMIZATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 216 JAPAN: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE, 2024-2031 (USD MILLION)
  • TABLE 217 JAPAN: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN ENGINEERING PROCESS, 2024-2031 (USD MILLION)
  • TABLE 218 JAPAN: AI IN PROTEIN ENGINEERING MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 219 INDIA: AI IN PROTEIN ENGINEERING MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 220 INDIA: AI IN PROTEIN ENGINEERING MARKET FOR SOFTWARE/PLATFORMS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 221 INDIA: AI IN PROTEIN ENGINEERING MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 222 INDIA: AI IN PROTEIN ENGINEERING MARKET, BY AI TOOL, 2024-2031 (USD MILLION)
  • TABLE 223 INDIA: AI IN PROTEIN ENGINEERING MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 224 INDIA: AI IN PROTEIN ENGINEERING MARKET FOR NEXT-GENERATION BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 225 INDIA: AI IN PROTEIN ENGINEERING MARKET FOR ANTIBODY DISCOVERY & OPTIMIZATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 226 INDIA: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE, 2024-2031 (USD MILLION)
  • TABLE 227 INDIA: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN ENGINEERING PROCESS, 2024-2031 (USD MILLION)
  • TABLE 228 INDIA: AI IN PROTEIN ENGINEERING MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 229 AUSTRALIA: AI IN PROTEIN ENGINEERING MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 230 AUSTRALIA: AI IN PROTEIN ENGINEERING MARKET FOR SOFTWARE/PLATFORMS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 231 AUSTRALIA: AI IN PROTEIN ENGINEERING MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 232 AUSTRALIA: AI IN PROTEIN ENGINEERING MARKET, BY AI TOOL, 2024-2031 (USD MILLION)
  • TABLE 233 AUSTRALIA: AI IN PROTEIN ENGINEERING MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 234 AUSTRALIA: AI IN PROTEIN ENGINEERING MARKET FOR NEXT-GENERATION BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 235 AUSTRALIA: AI IN PROTEIN ENGINEERING MARKET FOR ANTIBODY DISCOVERY & OPTIMIZATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 236 AUSTRALIA: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE, 2024-2031 (USD MILLION)
  • TABLE 237 AUSTRALIA: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN ENGINEERING PROCESS, 2024-2031 (USD MILLION)
  • TABLE 238 AUSTRALIA: AI IN PROTEIN ENGINEERING MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 239 SOUTH KOREA: AI IN PROTEIN ENGINEERING MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 240 SOUTH KOREA: AI IN PROTEIN ENGINEERING MARKET FOR SOFTWARE/PLATFORMS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 241 SOUTH KOREA: AI IN PROTEIN ENGINEERING MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 242 SOUTH KOREA: AI IN PROTEIN ENGINEERING MARKET, BY AI TOOL, 2024-2031 (USD MILLION)
  • TABLE 243 SOUTH KOREA: AI IN PROTEIN ENGINEERING MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 244 SOUTH KOREA: AI IN PROTEIN ENGINEERING MARKET FOR NEXT-GENERATION BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 245 SOUTH KOREA: AI IN PROTEIN ENGINEERING MARKET FOR ANTIBODY DISCOVERY & OPTIMIZATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 246 SOUTH KOREA: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE, 2024-2031 (USD MILLION)
  • TABLE 247 SOUTH KOREA: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN ENGINEERING PROCESS, 2024-2031 (USD MILLION)
  • TABLE 248 SOUTH KOREA: AI IN PROTEIN ENGINEERING MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 249 REST OF ASIA PACIFIC: AI IN PROTEIN ENGINEERING MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 250 REST OF ASIA PACIFIC: AI IN PROTEIN ENGINEERING MARKET FOR SOFTWARE/PLATFORMS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 251 REST OF ASIA PACIFIC: AI IN PROTEIN ENGINEERING MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 252 REST OF ASIA PACIFIC: AI IN PROTEIN ENGINEERING MARKET, BY AI TOOL, 2024-2031 (USD MILLION)
  • TABLE 253 REST OF ASIA PACIFIC: AI IN PROTEIN ENGINEERING MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 254 REST OF ASIA PACIFIC: AI IN PROTEIN ENGINEERING MARKET FOR NEXT-GENERATION BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 255 REST OF ASIA PACIFIC: AI IN PROTEIN ENGINEERING MARKET FOR ANTIBODY DISCOVERY & OPTIMIZATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 256 REST OF ASIA PACIFIC: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE, 2024-2031 (USD MILLION)
  • TABLE 257 REST OF ASIA PACIFIC: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN ENGINEERING PROCESS, 2024-2031 (USD MILLION)
  • TABLE 258 REST OF ASIA PACIFIC: AI IN PROTEIN ENGINEERING MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 259 LATIN AMERICA: AI IN PROTEIN ENGINEERING MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 260 LATIN AMERICA: AI IN PROTEIN ENGINEERING MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 261 LATIN AMERICA: AI IN PROTEIN ENGINEERING MARKET FOR SOFTWARE/PLATFORMS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 262 LATIN AMERICA: AI IN PROTEIN ENGINEERING MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 263 LATIN AMERICA: AI IN PROTEIN ENGINEERING MARKET, BY AI TOOL, 2024-2031 (USD MILLION)
  • TABLE 264 LATIN AMERICA: AI IN PROTEIN ENGINEERING MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 265 LATIN AMERICA: AI IN PROTEIN ENGINEERING MARKET FOR NEXT-GENERATION BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 266 LATIN AMERICA: AI IN PROTEIN ENGINEERING MARKET FOR ANTIBODY DISCOVERY & OPTIMIZATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 267 LATIN AMERICA: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE, 2024-2031 (USD MILLION)
  • TABLE 268 LATIN AMERICA: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN ENGINEERING PROCESS, 2024-2031 (USD MILLION)
  • TABLE 269 LATIN AMERICA: AI IN PROTEIN ENGINEERING MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 270 BRAZIL: AI IN PROTEIN ENGINEERING MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 271 BRAZIL: AI IN PROTEIN ENGINEERING MARKET FOR SOFTWARE/PLATFORMS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 272 BRAZIL: AI IN PROTEIN ENGINEERING MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 273 BRAZIL: AI IN PROTEIN ENGINEERING MARKET, BY AI TOOL, 2024-2031 (USD MILLION)
  • TABLE 274 BRAZIL: AI IN PROTEIN ENGINEERING MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 275 BRAZIL: AI IN PROTEIN ENGINEERING MARKET FOR NEXT-GENERATION BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 276 BRAZIL: AI IN PROTEIN ENGINEERING MARKET FOR ANTIBODY DISCOVERY & OPTIMIZATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 277 BRAZIL: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE, 2024-2031 (USD MILLION)
  • TABLE 278 BRAZIL: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN ENGINEERING PROCESS, 2024-2031 (USD MILLION)
  • TABLE 279 BRAZIL: AI IN PROTEIN ENGINEERING MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 280 MEXICO: AI IN PROTEIN ENGINEERING MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 281 MEXICO: AI IN PROTEIN ENGINEERING MARKET FOR SOFTWARE/PLATFORMS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 282 MEXICO: AI IN PROTEIN ENGINEERING MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 283 MEXICO: AI IN PROTEIN ENGINEERING MARKET, BY AI TOOL, 2024-2031 (USD MILLION)
  • TABLE 284 MEXICO: AI IN PROTEIN ENGINEERING MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 285 MEXICO: AI IN PROTEIN ENGINEERING MARKET FOR NEXT-GENERATION BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 286 MEXICO: AI IN PROTEIN ENGINEERING MARKET FOR ANTIBODY DISCOVERY & OPTIMIZATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 287 MEXICO: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE, 2024-2031 (USD MILLION)
  • TABLE 288 MEXICO: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN ENGINEERING PROCESS, 2024-2031 (USD MILLION)
  • TABLE 289 MEXICO: AI IN PROTEIN ENGINEERING MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 290 REST OF LATIN AMERICA: AI IN PROTEIN ENGINEERING MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 291 REST OF LATIN AMERICA: AI IN PROTEIN ENGINEERING MARKET FOR SOFTWARE/PLATFORMS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 292 REST OF LATIN AMERICA: AI IN PROTEIN ENGINEERING MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 293 REST OF LATIN AMERICA: AI IN PROTEIN ENGINEERING MARKET, BY AI TOOL, 2024-2031 (USD MILLION)
  • TABLE 294 REST OF LATIN AMERICA: AI IN PROTEIN ENGINEERING MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 295 REST OF LATIN AMERICA: AI IN PROTEIN ENGINEERING MARKET FOR NEXT-GENERATION BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 296 REST OF LATIN AMERICA: AI IN PROTEIN ENGINEERING MARKET FOR ANTIBODY DISCOVERY & OPTIMIZATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 297 REST OF LATIN AMERICA: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE, 2024-2031 (USD MILLION)
  • TABLE 298 REST OF LATIN AMERICA: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN ENGINEERING PROCESS, 2024-2031 (USD MILLION)
  • TABLE 299 REST OF LATIN AMERICA: AI IN PROTEIN ENGINEERING MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 300 MIDDLE EAST & AFRICA: AI IN PROTEIN ENGINEERING MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 301 MIDDLE EAST & AFRICA: AI IN PROTEIN ENGINEERING MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 302 MIDDLE EAST & AFRICA: AI IN PROTEIN ENGINEERING MARKET FOR SOFTWARE/PLATFORMS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 303 MIDDLE EAST & AFRICA: AI IN PROTEIN ENGINEERING MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 304 MIDDLE EAST & AFRICA: AI IN PROTEIN ENGINEERING MARKET, BY AI TOOL, 2024-2031 (USD MILLION)
  • TABLE 305 MIDDLE EAST & AFRICA: AI IN PROTEIN ENGINEERING MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 306 MIDDLE EAST & AFRICA: AI IN PROTEIN ENGINEERING MARKET FOR NEXT-GENERATION BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 307 MIDDLE EAST & AFRICA: AI IN PROTEIN ENGINEERING MARKET FOR ANTIBODY DISCOVERY & OPTIMIZATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 308 MIDDLE EAST & AFRICA: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE, 2024-2031 (USD MILLION)
  • TABLE 309 MIDDLE EAST & AFRICA: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN ENGINEERING PROCESS, 2024-2031 (USD MILLION)
  • TABLE 310 MIDDLE EAST & AFRICA: AI IN PROTEIN ENGINEERING MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 311 GCC COUNTRIES: AI IN PROTEIN ENGINEERING MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 312 GCC COUNTRIES: AI IN PROTEIN ENGINEERING MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 313 GCC COUNTRIES: AI IN PROTEIN ENGINEERING MARKET FOR SOFTWARE/PLATFORMS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 314 GCC COUNTRIES: AI IN PROTEIN ENGINEERING MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 315 GCC COUNTRIES: AI IN PROTEIN ENGINEERING MARKET, BY AI TOOL, 2024-2031 (USD MILLION)
  • TABLE 316 GCC COUNTRIES: AI IN PROTEIN ENGINEERING MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 317 GCC COUNTRIES: AI IN PROTEIN ENGINEERING MARKET FOR NEXT-GENERATION BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 318 GCC COUNTRIES: AI IN PROTEIN ENGINEERING MARKET FOR ANTIBODY DISCOVERY & OPTIMIZATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 319 GCC COUNTRIES: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE, 2024-2031 (USD MILLION)
  • TABLE 320 GCC COUNTRIES: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN ENGINEERING PROCESS, 2024-2031 (USD MILLION)
  • TABLE 321 GCC COUNTRIES: AI IN PROTEIN ENGINEERING MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 322 SAUDI ARABIA: AI IN PROTEIN ENGINEERING MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 323 SAUDI ARABIA: AI IN PROTEIN ENGINEERING MARKET FOR SOFTWARE/PLATFORMS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 324 SAUDI ARABIA: AI IN PROTEIN ENGINEERING MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 325 SAUDI ARABIA: AI IN PROTEIN ENGINEERING MARKET, BY AI TOOL, 2024-2031 (USD MILLION)
  • TABLE 326 SAUDI ARABIA: AI IN PROTEIN ENGINEERING MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 327 SAUDI ARABIA: AI IN PROTEIN ENGINEERING MARKET FOR NEXT-GENERATION BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 328 SAUDI ARABIA: AI IN PROTEIN ENGINEERING MARKET FOR ANTIBODY DISCOVERY & OPTIMIZATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 329 SAUDI ARABIA: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE, 2024-2031 (USD MILLION)
  • TABLE 330 SAUDI ARABIA: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN ENGINEERING PROCESS, 2024-2031 (USD MILLION)
  • TABLE 331 SAUDI ARABIA: AI IN PROTEIN ENGINEERING MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 332 UAE: AI IN PROTEIN ENGINEERING MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 333 UAE: AI IN PROTEIN ENGINEERING MARKET FOR SOFTWARE/PLATFORMS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 334 UAE: AI IN PROTEIN ENGINEERING MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 335 UAE: AI IN PROTEIN ENGINEERING MARKET, BY AI TOOL, 2024-2031 (USD MILLION)
  • TABLE 336 UAE: AI IN PROTEIN ENGINEERING MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 337 UAE: AI IN PROTEIN ENGINEERING MARKET FOR NEXT-GENERATION BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 338 UAE: AI IN PROTEIN ENGINEERING MARKET FOR ANTIBODY DISCOVERY & OPTIMIZATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 339 UAE: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE, 2024-2031 (USD MILLION)
  • TABLE 340 UAE: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN ENGINEERING PROCESS, 2024-2031 (USD MILLION)
  • TABLE 341 UAE: AI IN PROTEIN ENGINEERING MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 342 OTHER GCC COUNTRIES: AI IN PROTEIN ENGINEERING MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 343 OTHER GCC COUNTRIES: AI IN PROTEIN ENGINEERING MARKET FOR SOFTWARE/PLATFORMS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 344 OTHER GCC COUNTRIES: AI IN PROTEIN ENGINEERING MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 345 OTHER GCC COUNTRIES: AI IN PROTEIN ENGINEERING MARKET, BY AI TOOL, 2024-2031 (USD MILLION)
  • TABLE 346 OTHER GCC COUNTRIES: AI IN PROTEIN ENGINEERING MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 347 OTHER GCC COUNTRIES: AI IN PROTEIN ENGINEERING MARKET FOR NEXT-GENERATION BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 348 OTHER GCC COUNTRIES: AI IN PROTEIN ENGINEERING MARKET FOR ANTIBODY DISCOVERY & OPTIMIZATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 349 OTHER GCC COUNTRIES: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE, 2024-2031 (USD MILLION)
  • TABLE 350 OTHER GCC COUNTRIES: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN ENGINEERING PROCESS, 2024-2031 (USD MILLION)
  • TABLE 351 OTHER GCC COUNTRIES: AI IN PROTEIN ENGINEERING MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 352 SOUTH AFRICA: AI IN PROTEIN ENGINEERING MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 353 SOUTH AFRICA: AI IN PROTEIN ENGINEERING MARKET FOR SOFTWARE/PLATFORMS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 354 SOUTH AFRICA: AI IN PROTEIN ENGINEERING MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 355 SOUTH AFRICA: AI IN PROTEIN ENGINEERING MARKET, BY AI TOOL, 2024-2031 (USD MILLION)
  • TABLE 356 SOUTH AFRICA: AI IN PROTEIN ENGINEERING MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 357 SOUTH AFRICA: AI IN PROTEIN ENGINEERING MARKET FOR NEXT-GENERATION BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 358 SOUTH AFRICA: AI IN PROTEIN ENGINEERING MARKET FOR ANTIBODY DISCOVERY & OPTIMIZATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 359 SOUTH AFRICA: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE, 2024-2031 (USD MILLION)
  • TABLE 360 SOUTH AFRICA: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN ENGINEERING PROCESS, 2024-2031 (USD MILLION)
  • TABLE 361 SOUTH AFRICA: AI IN PROTEIN ENGINEERING MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 362 REST OF MIDDLE EAST & AFRICA: AI IN PROTEIN ENGINEERING MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 363 REST OF MIDDLE EAST & AFRICA: AI IN PROTEIN ENGINEERING MARKET FOR SOFTWARE/PLATFORMS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 364 REST OF MIDDLE EAST & AFRICA: AI IN PROTEIN ENGINEERING MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 365 REST OF MIDDLE EAST & AFRICA: AI IN PROTEIN ENGINEERING MARKET, BY AI TOOL, 2024-2031 (USD MILLION)
  • TABLE 366 REST OF MIDDLE EAST & AFRICA: AI IN PROTEIN ENGINEERING MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 367 REST OF MIDDLE EAST & AFRICA: AI IN PROTEIN ENGINEERING MARKET FOR NEXT-GENERATION BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 368 REST OF MIDDLE EAST & AFRICA: AI IN PROTEIN ENGINEERING MARKET FOR ANTIBODY DISCOVERY & OPTIMIZATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 369 REST OF MIDDLE EAST & AFRICA: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE, 2024-2031 (USD MILLION)
  • TABLE 370 REST OF MIDDLE EAST & AFRICA: AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN ENGINEERING PROCESS, 2024-2031 (USD MILLION)
  • TABLE 371 REST OF MIDDLE EAST & AFRICA: AI IN PROTEIN ENGINEERING MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 372 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN AI IN PROTEIN ENGINEERING MARKET, JANUARY 2023-SEPTEMBER 2026
  • TABLE 373 THE AI IN PROTEIN ENGINEERING MARKET: DEGREE OF COMPETITION
  • TABLE 374 AI IN PROTEIN ENGINEERING MARKET: REGION FOOTPRINT
  • TABLE 375 AI IN PROTEIN ENGINEERING MARKET: OFFERING FOOTPRINT
  • TABLE 376 AI IN PROTEIN ENGINEERING MARKET: APPLICATION FOOTPRINT
  • TABLE 377 AI IN PROTEIN ENGINEERING MARKET: AI TOOL FOOTPRINT
  • TABLE 378 AI IN PROTEIN ENGINEERING MARKET: END USER FOOTPRINT
  • TABLE 379 AI IN PROTEIN ENGINEERING MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS
  • TABLE 380 AI IN PROTEIN ENGINEERING MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS, BY REGION
  • TABLE 381 AI IN PROTEIN ENGINEERING MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS, BY OFFERING
  • TABLE 382 AI IN PROTEIN ENGINEERING MARKET: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 383 AI IN PROTEIN ENGINEERING MARKET: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 384 SCHRODINGER, INC.: COMPANY OVERVIEW
  • TABLE 385 SCHRODINGER, INC.: PRODUCTS OFFERED
  • TABLE 386 SCHRODINGER, INC.: PRODUCT ENHANCEMENTS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 387 SCHRODINGER, INC.: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 388 XTALPI: COMPANY OVERVIEW
  • TABLE 389 XTALPI: PRODUCTS OFFERED
  • TABLE 390 XTALPI: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 391 DASSAULT SYSTEMES: COMPANY OVERVIEW
  • TABLE 392 DASSAULT SYSTEMES: PRODUCTS OFFERED
  • TABLE 393 DASSAULT SYSTEMES: PRODUCT LAUNCHES/ENHANCEMENTS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 394 DASSAULT SYSTEMES: DEALS, JANUARY 2023- SEPTEMBER 2026
  • TABLE 395 NVIDIA CORPORATION: COMPANY OVERVIEW
  • TABLE 396 NVIDIA CORPORATION: PRODUCTS /SOLUTIONS OFFERED
  • TABLE 397 NVIDIA CORPORATION: PRODUCT LAUNCHES/ENHANCEMENTS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 398 NVIDIA CORPORATION: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 399 GENERATE:BIOMEDICINES: COMPANY OVERVIEW
  • TABLE 400 GENERATE:BIOMEDICINES: PRODUCTS OFFERED
  • TABLE 401 GENERATE:BIOMEDICINES: PRODUCT ENHANCEMENTS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 402 GENERATE:BIOMEDICINES: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 403 ABSCI CORP.: COMPANY OVERVIEW
  • TABLE 404 ABSCI CORP.: PRODUCTS OFFERED
  • TABLE 405 ABSCI CORP.: DEALS, JANUARY 2023- SEPTEMBER 2026
  • TABLE 406 INSILICO MEDICINE: COMPANY OVERVIEW
  • TABLE 407 INSILICO MEDICINE: PRODUCTS /SOLUTIONS OFFERED
  • TABLE 408 INSILICO MEDICINE: PRODUCT LAUNCHES/ENHANCEMENT, JANUARY 2023-SEPTEMBER 2026
  • TABLE 409 INSILICO MEDICINE: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 410 CRADLE: COMPANY OVERVIEW
  • TABLE 411 CRADLE: PRODUCTS OFFERED
  • TABLE 412 CRADLE: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 413 CRADLE: OTHER DEVELOPMENTS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 414 A-ALPHA BIO, INC.: COMPANY OVERVIEW
  • TABLE 415 A-ALPHA BIO, INC.: PRODUCTS OFFERED
  • TABLE 416 A-ALPHA BIO, INC.: PRODUCT LAUNCHES, JANUARY 2023-SEPTEMBER 2026
  • TABLE 417 A-ALPHA BIO, INC.: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 418 A-ALPHA BIO, INC.: OTHER DEVELOPMENTS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 419 ISOMORPHIC LABS: COMPANY OVERVIEW
  • TABLE 420 ISOMORPHIC LABS: PRODUCTS OFFERED
  • TABLE 421 ISOMORPHIC LABS: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 422 ISOMORPHIC LABS: OTHER DEVELOPMENTS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 423 CHAI DISCOVERY: COMPANY OVERVIEW
  • TABLE 424 CHAI DISCOVERY: PRODUCTS OFFERED
  • TABLE 425 CHAI DISCOVERY: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 426 CHAI DISCOVERY: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 427 CHAI DISCOVERY: OTHER DEVELOPMENTS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 428 EVOLUTIONARYSCALE (BIOHUB): COMPANY OVERVIEW
  • TABLE 429 EVOLUTIONARYSCALE (BIOHUB): PRODUCTS OFFERED
  • TABLE 430 EVOLUTIONARYSCALE (BIOHUB): PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 431 EVOLUTIONARYSCALE (BIOHUB): DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 432 EVOLUTIONARYSCALE (BIOHUB): OTHER DEVELOPMENTS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 433 PROFLUENT: COMPANY OVERVIEW
  • TABLE 434 PROFLUENT: PRODUCTS OFFERED
  • TABLE 435 PROFLUENT: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 436 PROFLUENT: OTHER DEVELOPMENTS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 437 BIGHAT BIO: COMPANY OVERVIEW
  • TABLE 438 BIGHAT BIO: PRODUCTS OFFERED
  • TABLE 439 BIGHAT BIO: PRODUCT LAUNCHES, JANUARY 2023-SEPTEMBER 2026
  • TABLE 440 BIGHAT BIO: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 441 LATENT LABS: COMPANY OVERVIEW
  • TABLE 442 LATENT LABS: PRODUCTS OFFERED
  • TABLE 443 LATENT LABS: PRODUCT LAUNCHES, JANUARY 2023-SEPTEMBER 2026
  • TABLE 444 LATENT LABS: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 445 LATENT LABS: OTHER DEVELOPMENTS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 446 BASECAMP RESEARCH: COMPANY OVERVIEW
  • TABLE 447 BASECAMP RESEARCH: PRODUCTS OFFERED
  • TABLE 448 BASECAMP RESEARCH: PRODUCT LAUNCHES, JANUARY 2023-SEPTEMBER 2026
  • TABLE 449 BASECAMP RESEARCH: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 450 BASECAMP RESEARCH: OTHER DEVELOPMENTS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 451 NABLA BIO, INC.: COMPANY OVERVIEW
  • TABLE 452 NABLA BIO, INC.: PRODUCTS OFFERED
  • TABLE 453 NABLA BIO, INC.: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 454 NABLA BIO, INC.: OTHER DEVELOPMENTS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 455 EVOZYNE: COMPANY OVERVIEW
  • TABLE 456 EVOZYNE: PRODUCTS OFFERED
  • TABLE 457 EVOZYNE: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 458 EVOZYNE: OTHER DEVELOPMENTS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 459 LABGENIUS LIMITED: COMPANY OVERVIEW
  • TABLE 460 LABGENIUS LIMITED: PRODUCTS OFFERED
  • TABLE 461 LABGENIUS LIMITED: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 462 LABGENIUS LIMITED: OTHER DEVELOPMENTS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 463 ARZEDA CORPORATION: COMPANY OVERVIEW
  • TABLE 464 MENTEN AI: COMPANY OVERVIEW
  • TABLE 465 PROTEINQURE: COMPANY OVERVIEW
  • TABLE 466 OUTPACE BIO: COMPANY OVERVIEW
  • TABLE 467 AI PROTEINS: COMPANY OVERVIEW
  • TABLE 468 MONODBIO: COMPANY OVERVIEW
  • TABLE 469 BIOMATTER INC.: COMPANY OVERVIEW
  • TABLE 470 DIFFUSE BIO: COMPANY OVERVIEW
  • TABLE 471 RISK ASSESSMENT: AI IN PROTEIN ENGINEERING MARKET

List of Figures

  • FIGURE 1 AI IN PROTEIN ENGINEERING MARKET SEGMENTATION
  • FIGURE 2 MARKET SCENARIO
  • FIGURE 3 GLOBAL AI IN PROTEIN ENGINEERING MARKET, 2024-2031
  • FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN AI IN PROTEIN ENGINEERING MARKET, 2023-2026
  • FIGURE 5 DISRUPTIONS INFLUENCING GROWTH OF AI IN PROTEIN ENGINEERING MARKET
  • FIGURE 6 HIGH-GROWTH SEGMENTS IN AI IN PROTEIN ENGINEERING MARKET, 2026-2031
  • FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN AI IN PROTEIN ENGINEERING MARKET DURING FORECAST PERIOD
  • FIGURE 8 INCREASING R&D INVESTMENTS IN PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRIES TO DRIVE GROWTH IN AI IN PROTEIN ENGINEERING MARKET
  • FIGURE 9 SOFTWARE/PLATFORMS HELD MAJOR SHARE IN NORTH AMERICA IN 2025
  • FIGURE 10 INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • FIGURE 11 AI IN PROTEIN ENGINEERING MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 12 AI IN PROTEIN ENGINEERING MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 13 AI IN PROTEIN ENGINEERING MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • FIGURE 16 PATENT PUBLICATION TRENDS IN AI IN PROTEIN ENGINEERING MARKET, 2015-2026
  • FIGURE 17 JURISDICTION AND TOP APPLICANT ANALYSIS FOR AI IN PROTEIN ENGINEERING MARKET
  • FIGURE 18 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR AI IN PROTEIN ENGINEERING MARKET (JANUARY 2015 TO JUNE 2026)
  • FIGURE 19 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS
  • FIGURE 20 KEY BUYING CRITERIA FOR TOP THREE END USERS
  • FIGURE 21 NORTH AMERICA: AI IN PROTEIN ENGINEERING MARKET SNAPSHOT
  • FIGURE 22 ASIA PACIFIC: AI IN PROTEIN ENGINEERING MARKET SNAPSHOT
  • FIGURE 23 AI IN PROTEIN ENGINEERING MARKET: REVENUE ANALYSIS OF KEY PLAYERS
  • FIGURE 24 AI IN PROTEIN ENGINEERING MARKET SHARE ANALYSIS OF KEY PLAYERS (2025)
  • FIGURE 25 AI IN PROTEIN ENGINEERING MARKET: BRAND COMPARATIVE ANALYSIS
  • FIGURE 26 EV/EBITDA OF KEY VENDORS
  • FIGURE 27 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 28 AI IN PROTEIN ENGINEERING MARKET: COMPANY EVALUATION MATRIX (2025)
  • FIGURE 29 AI IN PROTEIN ENGINEERING MARKET: COMPANY FOOTPRINT
  • FIGURE 30 AI IN PROTEIN ENGINEERING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
  • FIGURE 31 SCHRODINGER, INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 32 XTALPI: COMPANY SNAPSHOT (2025)
  • FIGURE 33 DASSAULT SYSTEMES: COMPANY SNAPSHOT (2025)
  • FIGURE 34 NVIDIA CORPORATION: COMPANY SNAPSHOT (2025)
  • FIGURE 35 ABSCI CORP.: COMPANY SNAPSHOT (2025)
  • FIGURE 36 INSILICO MEDICINE: COMPANY SNAPSHOT (2025)
  • FIGURE 37 RESEARCH DESIGN
  • FIGURE 38 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 39 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
  • FIGURE 40 BOTTOM-UP APPROACH
  • FIGURE 41 TOP-DOWN APPROACH
  • FIGURE 42 CAGR PROJECTIONS FROM ANALYSIS OF MARKET DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF AI IN PROTEIN ENGINEERING INDUSTRY
  • FIGURE 43 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 44 DATA TRIANGULATION METHODOLOGY
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!